Skip to content
Open Data Finder

Search results for Summary Safety Review

Filters

102 datasets for “Summary Safety Review”

  1. Open Government Canada

    Summary Safety Review - MELATONIN (N-acetyl-5-methoxytryptamine) - Review of the Safety of Melatonin in Children and Adolescents

    Health Canada | Santé CanadaUpdated 9 May 2024

    … 18 years old (pediatric population), Health Canada did a review of this safety issue in this age group.

    • HTML
  2. Open Government Canada

    Summary Safety Review - DICLECTIN (doxylamine and pyridoxine combination) - Assessing Safety in pregnancy

    Health Canada | Santé CanadaUpdated 8 May 2024

    … The safety of Diclectin was recently reviewed by Health Canada as part of its routine health product monitoring …

    • HTML
  3. Open Government Canada

    Review Summary Report - Pre-licensing Review of NMWO’s Proposed Preliminary Safety Assessment Acceptance Criteria

    Canadian Nuclear Safety Commission | Commission canadienne de sûreté nucléaireUpdated 2 Apr 2026

    The NWMO requested Canadian Nuclear Safety Commission (CNSC) staff to conduct a pre-licensing technical review of its …

    • PDF
  4. Open Government Canada

    Summary Safety Review - Propecia (finasteride 1 mg) and Proscar (finasteride 5 mg) - Assessing the Potential Risk of Seizures

    Health Canada | Santé CanadaUpdated 10 May 2024

    Health Canada carried out a safety review to look at the potential risk of seizures in patients taking …

    • HTML
  5. Open Government Canada

    Summary Safety Review - PRADAXA (dabigatran etexilate) - Assessing the potential risk of liver injury

    Health Canada | Santé CanadaUpdated 10 May 2024

    Health Canada reviewed the potential risk of liver injury with Pradaxa after receiving reports of severe liver injury …

    • HTML
  6. Open Government Canada

    Summary Safety Review - Celecoxib - Assessing the Risk of Serious Heart and Stroke Side Effects at High Doses Relative to Other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)

    Health Canada | Santé CanadaUpdated 8 May 2024

    Health Canada carried out a safety review of all the available evidence to evaluate the risk of side …

    • HTML
  7. Open Government Canada

    Summary Safety Review - Green tea extract-containing natural health products - Assessing the potential risk of liver injury (hepatotoxicity)

    Health Canada | Santé CanadaUpdated 9 May 2024

    Health Canada reviewed the potential risk of liver injury with green tea extract-containing natural health products because …

    • HTML
  8. Open Government Canada

    Summary Safety Review - ABILIFY and ABILIFY MAINTENA (aripiprazole) - Evaluating the Risk of Certain Impulse Control Behaviours

    Health Canada | Santé CanadaUpdated 8 May 2024

    A safety review was conducted to evaluate the potential link between Abilify and Abilify Maintena (aripiprazole) and certain …

    • HTML
  9. Open Government Canada

    Summary Safety Review - Fluoroquinolones - Assessing the potential risk of persistent and disabling side effects

    Health Canada | Santé CanadaUpdated 9 May 2024

    Health Canada started a safety review following a review done by the FDA on systemic (taken by mouth …

    • HTML
  10. Open Government Canada

    Summary Safety Review - Over-the-Counter Products Containing Pseudoephedrine - Assessing the Potential Risk of Inflammation and Injury of the Large Intestine due to Insufficient Blood Supply (ischemic colitis)

    Health Canada | Santé CanadaUpdated 10 May 2024

    Summary Safety Review - Over-the-Counter Products Containing Pseudoephedrine - Assessing the Potential Risk of Inflammation and Injury of …

    • HTML
  11. Open Government Canada

    Summary Safety Review - Intraocular lenses - Assessing the potential risk of developing small pockets of liquid in intraocular lenses (glistening)

    Health Canada | Santé CanadaUpdated 9 May 2024

    … Health Canada has been actively monitoring reports of IOL glistening since 2012, with additional safety reviews completed in …

    • HTML
  12. Open Government Canada

    Summary Safety Review - Finasteride - Assessing the Potential Risk of Suicidal Thoughts and Behaviour (Suicidality)

    Health Canada | Santé CanadaUpdated 9 May 2024

    This safety review was carried out as a follow-up assessment on the potential risk of suicidality with …

    • HTML
  13. Open Government Canada

    Summary Safety Review - Proton Pump Inhibitors (PPIs) - Assessing the risk of a type of skin reaction [Subacute Cutaneous Lupus Erythematosus (SCLE)]

    Health Canada | Santé CanadaUpdated 10 May 2024

    Health Canada reviewed the potential risk of a type of skin reaction known as subacute cutaneous lupus erythematosus …

    • HTML
  14. Open Government Canada

    Summary Safety Review - Hydroxyzine (ATARAX and generics) - Assessing the Potential Risk of Abnormal Heart Rhythm

    Health Canada | Santé CanadaUpdated 9 May 2024

    A safety review was undertaken soon after the European Medicines Agency notified Health Canada of the possibility that …

    • HTML
  15. Open Government Canada

    Summary Safety Review - Omnipod Insulin Management System - Assessing the potential risk of malfunctions with the device

    Health Canada | Santé CanadaUpdated 9 May 2024

    In 2014, Health Canada completed a first safety review for the Omnipod because a high number of complaints …

    • HTML
  16. Open Government Canada

    Summary Safety Review - Levetiracetam and Methotrexate - Assessing the Potential Risk of Drug-Drug Interaction

    Health Canada | Santé CanadaUpdated 9 May 2024

    Health Canada carried out a safety review after learning that the European Medicines Agency was looking into a …

    • HTML
  17. Open Government Canada

    Summary Safety Review - ZOFRAN (ondansetron) - Assessing the Potential Harm to the Fetus

    Health Canada | Santé CanadaUpdated 10 May 2024

    Health Canada carried out a safety review to assess the risk of birth defects with the use of …

    • HTML
  18. Open Government Canada

    Summary Safety Review - Atypical antipsychotics - Assessing the Potential Risk of Urinary Retention

    Health Canada | Santé CanadaUpdated 8 May 2024

    Health Canada carried out a safety review to look into the use of atypical antipsychotics and the potential …

    • HTML
  19. Open Government Canada

    Summary Safety Review - Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors INVOKANA (canagliflozin) and FORXIGA (dapagliflozin) - Evaluation of a Potential Risk of Acute Kidney Injury

    Health Canada | Santé CanadaUpdated 10 May 2024

    A safety review was done to evaluate the potential risk of acute kidney injury and the use of …

    • HTML
  20. Open Government Canada

    Summary Safety Review - Atypical antipsychotics - Assessing the Potential Risk of Sleep Apnoea

    Health Canada | Santé CanadaUpdated 8 May 2024

    Health Canada carried out a safety review to look into the risk of sleep apnoea with the use …

    • HTML
“Summary Safety Review” datasets · Open Data Finder